BioNTech SE (NASDAQ:BNTX) – Equities researchers at Jefferies Financial Group issued their Q1 2022 EPS estimates for BioNTech in a research report issued on Tuesday, November 9th. Jefferies Financial Group analyst A. Tewari expects that the company will post earnings of $7.69 per share for the quarter. Jefferies Financial Group also issued estimates for BioNTech’s Q4 2022 earnings at $6.57 EPS.
BNTX has been the subject of several other reports. Deutsche Bank Aktiengesellschaft began coverage on BioNTech in a research note on Friday, October 22nd. They set a “hold” rating and a $250.00 target price for the company. HC Wainwright raised BioNTech from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $242.00 to $360.00 in a report on Wednesday. Wolfe Research began coverage on BioNTech in a report on Monday, July 19th. They set an “outperform” rating and a $248.00 price target for the company. TheStreet downgraded BioNTech from a “b-” rating to a “c+” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. set a $180.00 price target on BioNTech in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $272.29.
Shares of NASDAQ BNTX opened at $235.89 on Friday. BioNTech has a twelve month low of $80.55 and a twelve month high of $464.00. The company has a current ratio of 2.67, a quick ratio of 2.57 and a debt-to-equity ratio of 0.04. The stock has a fifty day simple moving average of $288.70 and a 200-day simple moving average of $268.02. The stock has a market capitalization of $57.21 billion, a PE ratio of 12.34 and a beta of -1.22. BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 8th. The company reported $12.35 earnings per share for the quarter, beating the Zacks’ consensus estimate of $10.54 by $1.81. BioNTech had a return on equity of 159.73% and a net margin of 52.48%. The business had revenue of $6.09 billion during the quarter, compared to analysts’ expectations of $5.02 billion. During the same period in the previous year, the firm posted ($1.03) earnings per share. The company’s revenue was up 8918.2% on a year-over-year basis.
Several institutional investors have recently bought and sold shares of the company. Jennison Associates LLC lifted its holdings in shares of BioNTech by 1,473.7% in the 3rd quarter. Jennison Associates LLC now owns 4,073,570 shares of the company’s stock valued at $1,112,044,000 after purchasing an additional 3,814,715 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of BioNTech by 31.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,074,906 shares of the company’s stock valued at $226,559,000 after purchasing an additional 500,085 shares during the last quarter. FMR LLC increased its position in BioNTech by 13.8% in the 2nd quarter. FMR LLC now owns 1,997,013 shares of the company’s stock valued at $447,092,000 after acquiring an additional 242,867 shares during the period. Fosun International Ltd acquired a new position in BioNTech in the 2nd quarter valued at about $353,904,000. Finally, BlackRock Inc. increased its position in BioNTech by 99.4% in the 2nd quarter. BlackRock Inc. now owns 1,481,390 shares of the company’s stock valued at $331,654,000 after acquiring an additional 738,532 shares during the period. 14.34% of the stock is owned by institutional investors and hedge funds.
BioNTech Company Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors.